A detailed history of Sg Americas Securities, LLC transactions in Aurinia Pharmaceuticals Inc. stock. As of the latest transaction made, Sg Americas Securities, LLC holds 12,426 shares of AUPH stock, worth $90,212. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,426
Previous 14,190 12.43%
Holding current value
$90,212
Previous $71,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 12, 2024

SELL
$4.81 - $5.78 $8,484 - $10,195
-1,764 Reduced 12.43%
12,426 $71,000
Q1 2024

May 06, 2024

SELL
$4.93 - $9.31 $103,613 - $195,668
-21,017 Reduced 59.7%
14,190 $71,000
Q4 2023

Jan 12, 2024

BUY
$7.13 - $9.49 $99,998 - $133,097
14,025 Added 66.21%
35,207 $317,000
Q3 2023

Oct 13, 2023

BUY
$7.77 - $12.27 $164,584 - $259,903
21,182 New
21,182 $165,000
Q2 2022

Jul 29, 2022

SELL
$8.95 - $12.8 $6.97 Million - $9.97 Million
-779,071 Reduced 97.24%
22,126 $222,000
Q1 2022

Apr 29, 2022

BUY
$10.05 - $22.48 $1.46 Million - $3.26 Million
144,992 Added 22.1%
801,197 $9.92 Million
Q4 2021

Feb 07, 2022

BUY
$17.78 - $33.08 $4.36 Million - $8.12 Million
245,417 Added 59.74%
656,205 $15 Million
Q3 2021

Nov 01, 2021

BUY
$10.93 - $23.55 $2.66 Million - $5.74 Million
243,678 Added 145.82%
410,788 $9.09 Million
Q2 2021

Aug 12, 2021

BUY
$10.0 - $14.52 $943,780 - $1.37 Million
94,378 Added 129.76%
167,110 $2.17 Million
Q1 2021

May 13, 2021

BUY
$12.3 - $18.73 $894,603 - $1.36 Million
72,732 New
72,732 $944,000
Q1 2020

Apr 30, 2020

SELL
$11.34 - $21.46 $57,890 - $109,553
-5,105 Closed
0 $0
Q4 2019

Jan 28, 2020

SELL
$3.88 - $21.42 $159,114 - $878,412
-41,009 Reduced 88.93%
5,105 $103,000
Q3 2019

Nov 04, 2019

BUY
$5.34 - $6.59 $246,248 - $303,891
46,114 New
46,114 $246,000

Others Institutions Holding AUPH

About Aurinia Pharmaceuticals Inc.


  • Ticker AUPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,892,000
  • Market Cap $1.03B
  • Description
  • Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...
More about AUPH
Track This Portfolio

Track Sg Americas Securities, LLC Portfolio

Follow Sg Americas Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg Americas Securities, LLC with notifications on news.